News headlines about Halozyme (NASDAQ:HALO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Halozyme earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.1753468819679 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
Get Halozyme alerts:
Halozyme Therapeutics, Inc. (HALO): Stock under Close Observation: (mosttradedstocks.com) Notable Volatile Movements: Halozyme Therapeutics, Inc. (NASDAQ: HALO) (productioninvestments.com) What is The Actual Stock’s Value Complete Picture in Focus Halozyme Therapeutics (NASDAQ:HALO) (nasdaqjournal.com) Halozyme Therapeutic (HALO)’s Weekly Performance of -2.33% Is Nothing to Write Home About (parkcitycaller.com) Alluring Stocks Halozyme Therapeutics, Inc., NASDAQ: HALO) (dailynysenews.com)
HALO has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Halozyme from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Wednesday, January 24th. Goldman Sachs initiated coverage on Halozyme in a research report on Wednesday, January 24th. They set a “neutral” rating and a $20.00 target price on the stock. Deutsche Bank set a $21.00 target price on Halozyme and gave the stock a “buy” rating in a research report on Wednesday, January 24th. JPMorgan Chase reiterated an “overweight” rating and set a $22.00 target price (up from $19.00) on shares of Halozyme in a research report on Wednesday, February 21st. Finally, Canaccord Genuity boosted their target price on Halozyme from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $19.89.
NASDAQ HALO opened at $19.87 on Tuesday. Halozyme has a fifty-two week low of $18.93 and a fifty-two week high of $19.97. The firm has a market capitalization of $2.71 billion, a PE ratio of 44.16 and a beta of 1.88. The company has a quick ratio of 4.03, a current ratio of 4.06 and a debt-to-equity ratio of 0.39.
Halozyme (NASDAQ:HALO) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.03. Halozyme had a return on equity of 45.31% and a net margin of 21.52%. The company had revenue of $30.90 million during the quarter, compared to analysts’ expectations of $31.84 million. During the same period in the previous year, the firm posted ($0.26) earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. research analysts predict that Halozyme will post -0.82 earnings per share for the current fiscal year.
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
HALO)' title='News Sentimetn History for Halozyme (NASDAQ:HALO)' />